Act Two Investors’s AstraZeneca AZN Stock Holding History

Act Two Investors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-175,888	Closed	-$32.3M	–	38
2025 Q4	$32.3M	Sell	175,888 -6,145	-3%	-$1.08M	5.82%	6
2025 Q3	$27.9M	Sell	182,033 -223	-0.1%	-$33.8K	4.95%	8
2025 Q2	$25.5M	Buy	182,256 +46,087	+34%	+$6.46M	5.2%	8
2025 Q1	$20M	Buy	136,169 +69,471	+104%	+$10.1M	4.24%	9
2024 Q4	$8.74M	Sell	66,698 -93,722	-58%	-$13.1M	1.7%	16
2024 Q3	$25M	Buy	160,420 +441	+0.3%	+$71.2K	4.72%	9
2024 Q2	$25M	Buy	159,979 +8,250	+5%	+$1.24M	4.94%	8
2024 Q1	$20.6M	Buy	+151,729	New	+$20.1M	4.13%	10

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Act Two Investors's AZN Position: Q1 2026 in Review

Act Two Investors sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 175,888 shares — an estimated $32.3M sold.

Act Two Investors first reported a position in AZN in Q1 2024 and held it in 8 quarters. The position peaked at $32.3M in Q4 2025. 1,379 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Act Two Investors reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
Act Two Investors sold 175,888 AstraZeneca shares in Q1 2026, an estimated $32.3M.
Act Two Investors first reported a position in AstraZeneca in Q1 2024 and held it in 8 quarters.
Act Two Investors's AstraZeneca position peaked at $32.3M in Q4 2025.
1,379 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Act Two Investors's 13F filing for Q1 2026, filed 8 May 2026.